Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

LongBio Pharma (Suzhou) / Equity Capital Markets

<ul>
<li>LongBio Pharma, a clinical-stage biopharmaceutical company, has launched its HK IPO consisting of 14M H shares. The offer price has been fixed at HK$96.06 per share.</li>
<li>The company intends to raise HK$1,345M, primarily for the R&amp;D and commercialization of core product and key product, and further development of other pre-clinical pipeline products and R&amp;D platforms.</li>
<li>The subscription period will close on June 2, 2026, with the shares expected to make trading debut on June 5, 2026.</li>
</ul>


LongBio Pharma, a clinical-stage biopharmaceutical company, has launched its HK IPO consisting of 14M H shares. The offer price has been fixed at HK$96.06 per share.
The company intends to raise HK$1,345M, primarily for the R&amp;D and commercialization of core product and key product, and further development of other pre-clinical pipeline products and R&amp;D platforms.
The subscription period will close on June 2, 2026, with the shares expected to make trading debut on June 5, 2026.


LongBio Pharma IPO: Not Enough Prospective Yet to Prevent Investor Allergy